Big Cap Pharma Overlooked in XBI Move?
The healthcare space continues to act well, as it is the best performing major S&P sector on a 6 month look back period higher by nearly 11%. The space has the allure of both capital appreciation and nice dividend yields. Leading names will offer investors to add to their positions on the way up, and today we will look at that with a past and present view of NVS. Below is how we looked at NVS in our 10/9 Healthcare Note. Swiss pharma play UNCH both on a YTD and over last one year period. Dividend yield of 3.3%. Lower 8 of the last 11 weeks, and one would think would be lower than the 10% it is off from most recent 52 week highs. FOUR consecutive positive earnings reactions higher by 4.5, 2.5, 2.2 and 1.1% on 7/18, 4/24, 1/31 and 10/18/18. Enter here after recent gap fill and support at upward sloping 200 day SMA. Entry NVS here. Stop 82 (REPORTS 10/22 before open).